SBTi

WuXi Biologics (2269.HK) announced SBTi approval of its near-term and net-zero GHG emissions reduction targets, aligning with 1.5°C pathways and committing to net-zero across its value chain by 2050. As a leading Green CRDMO, WuXi Biologics implements a comprehensive strategy, engaging suppliers to reduce its environmental footprint. CEO Dr. Chris Chen views this as a catalyst for further action and delivering ESG excellence. The company holds MSCI AAA Rating, EcoVadis Platinum Medal, and DJSI listing.